You do not currently have access to this content.
AbstractBackground:. Wildfires are becoming more frequent and severe, reversing decades of progress in reducing fine particulate matter (PM2.5) in the United States. Although wildfire smoke (WFS) ...
With its remarkable potency in driving CDK4 degradation and superior selectivity over CDK6, BLU-448 holds promise as a potential best-in-class treatment for HR+/HER2- breast cancers —and possibly ...
13Huntsman Cancer Institute, Salt Lake City, UT.
Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, ...
Search for other works by this author on: ...
AbstractBackground:. Computational pathology has successfully incorporated artificial intelligence (AI) methodologies for various applications, including the predictions of therapeutic response, ...
Abstract. PD-L1 is an established immunotherapy target highly expressed in various solid tumors, while B7-H3 is another extensively investigated target overexpressed on a wide range of tumor cells.
Xinyi Pharma (Hangzhou) Co., Ltd., Hangzhou, China.
1Peking University First Hospital, Department of Urology, Peking, China, Beijing, China.
In DESTINY-Breast03 (NCT03529110), T-DXd showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) vs T-DM1 in pts with HER2+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results